Table of Contents Author Guidelines Submit a Manuscript
International Journal of Microbiology
Volume 2012, Article ID 713687, 26 pages
http://dx.doi.org/10.1155/2012/713687
Review Article

Antifungal Resistance and New Strategies to Control Fungal Infections

Institute of Microbiology, University of Lausanne and University Hospital, Rue du Bugnon 48, 1011 Lausanne, Switzerland

Received 21 July 2011; Accepted 6 September 2011

Academic Editor: Arianna Tavanti

Copyright © 2012 Patrick Vandeputte et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Morishita and Y. Sei, “Microreview of Pityriasis versicolor and Malassezia species,” Mycopathologia, vol. 162, no. 6, pp. 373–376, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. J. Thomas, G. A. Jacobson, C. K. Narkowicz, G. M. Peterson, H. Burnet, and C. Sharpe, “Toenail onychomycosis: an important global disease burden,” Journal of Clinical Pharmacy and Therapeutics, vol. 35, no. 5, pp. 497–519, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. R. D. Diamond, “The growing problem of mycoses in patients infected with the human immunodeficiency virus,” Reviews of Infectious Diseases, vol. 13, no. 3, pp. 480–486, 1991. View at Google Scholar · View at Scopus
  4. M. C. Arendrup, “Epidemiology of invasive candidiasis,” Current Opinion in Critical Care, vol. 16, no. 5, pp. 445–452, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. T. J. Walsh and D. M. Dixon, “Spectrum of mycoses,” in Medical Microbiology, S. Baron, Ed., Galveston, Tex, USA, 1996. View at Google Scholar
  6. J. Eucker, O. Sezer, B. Graf, and K. Possinger, “Mucormycoses,” Mycoses, vol. 44, no. 7-8, pp. 253–260, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Duschinsky, E. Pleven, and W. Oberhansli, “Synthesis of 5-fluoropyrimidine metabolites,” Acta—Unio Internationalis Contra Cancrum, vol. 16, pp. 599–604, 1960. View at Google Scholar · View at Scopus
  8. E. Grunberg, E. Titsworth, and M. Bennett, “Chemotherapeutic activity of 5-fluorocytosine,” Antimicrobial Agents and Chemotherapy, vol. 161, pp. 566–568, 1963. View at Google Scholar
  9. D. Tassel and M. A. Madoff, “Treatment of Candida sepsis and Cryptococcus meningitis with 5-fluorocytosine. A new antifungal agent,” Journal of the American Medical Association, vol. 206, no. 4, pp. 830–832, 1968. View at Publisher · View at Google Scholar · View at Scopus
  10. R. L. Stiller, J. E. Bennett, and H. J. Scholer, “Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model,” The Journal of Infectious Diseases, vol. 147, no. 6, pp. 1070–1077, 1983. View at Google Scholar · View at Scopus
  11. A. Vermes, H. J. Guchelaar, and J. Dankert, “Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions,” The Journal of Antimicrobial Chemotherapy, vol. 46, no. 2, pp. 171–179, 2000. View at Google Scholar
  12. T. K. Daneshmend and D. W. Warnock, “Clinical pharmacokinetics of systemic antifungal drugs,” Clinical Pharmacokinetics, vol. 8, no. 1, pp. 17–42, 1983. View at Google Scholar
  13. A. M. Stamm, R. B. Diasio, W. E. Dismukes et al., “Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis,” American Journal of Medicine, vol. 83, no. 2, pp. 236–242, 1987. View at Google Scholar
  14. P. Francis and T. J. Walsh, “Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy,” Clinical Infectious Diseases, vol. 15, no. 6, pp. 1003–1018, 1992. View at Google Scholar
  15. C. A. Kauffman and P. T. Frame, “Bone marrow toxicity associated with 5 fluorocytosine therapy,” Antimicrobial Agents and Chemotherapy, vol. 11, no. 2, pp. 244–247, 1977. View at Google Scholar
  16. A. Polak and H. J. Scholer, “Mode of action of 5 fluorocytosine and mechanisms of resistance,” Chemotherapy, vol. 21, no. 3-4, pp. 113–130, 1975. View at Google Scholar · View at Scopus
  17. R. Diasio, D. Lakings, and J. Bennett, “Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans: possible factor in 5-fluorocytosine clinical toxicity,” Antimicrobial Agents and Chemotherapy, vol. 14, no. 6, pp. 903–908, 1978. View at Google Scholar · View at Scopus
  18. K. M. Williams, A. M. Duffield, R. K. Christopher, and P. J. Finlayson, “Identification of minor metabolites of 5-fluorocytosine in man by chemical ionization gas chromatography mass spectrometry,” Biomedical Mass Spectrometry, vol. 8, no. 4, pp. 179–182, 1981. View at Google Scholar · View at Scopus
  19. B. E. Harris, B. W. Manning, T. W. Federle, and R. B. Diasio, “Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora,” Antimicrobial Agents and Chemotherapy, vol. 29, no. 1, pp. 44–48, 1986. View at Google Scholar · View at Scopus
  20. J. M. Benson and M. C. Nahata, “Clinical use of systemic antifungal agents,” Clinical Pharmacy, vol. 7, no. 6, pp. 424–438, 1988. View at Google Scholar · View at Scopus
  21. J. E. Bennett, W. E. Dismukes, and R. J. Duma, “A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis,” New England Journal of Medicine, vol. 301, no. 3, pp. 126–131, 1979. View at Google Scholar · View at Scopus
  22. R. Patel, “Antifungal agents. Part I. Amphotericin B preparations and flucytosine,” Mayo Clinic Proceedings, vol. 73, no. 12, pp. 1205–1225, 1998. View at Google Scholar · View at Scopus
  23. D. R. Hospenthal and J. E. Bennett, “Flucytosine monotherapy for cryptococcosis,” Clinical Infectious Diseases, vol. 27, no. 2, pp. 260–264, 1998. View at Google Scholar
  24. A. Polak and M. Grenson, “Evidence for a common transport system for cytosine, adenine and hypoxanthine in Saccharomyces cerevisiae and Candida albicans,” European Journal of Biochemistry, vol. 32, no. 2, pp. 276–282, 1973. View at Google Scholar · View at Scopus
  25. A. R. Waldorf and A. Polak, “Mechanisms of action of 5-fluorocytosine,” Antimicrobial Agents and Chemotherapy, vol. 23, no. 1, pp. 79–85, 1983. View at Google Scholar · View at Scopus
  26. J. E. Bennett, “Antifungal agents,” in Goodman and Gilman's The Pharmacological Basis of Therapeurics, J. G. Hardman et al., Ed., pp. 1175–1190, McGraw-Hill, New York, NY, USA, 1996. View at Google Scholar
  27. P. Caffrey, S. Lynch, E. Flood, S. Finnan, and M. Oliynyk, “Amphotericin biosynthesis in Streptomyces nodosus: deductions from analysis of polyketide synthase and late genes,” Chemistry and Biology, vol. 8, no. 7, pp. 713–723, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Lemke, A. F. Kiderlen, and O. Kayser, “Amphotericin B,” Applied Microbiology and Biotechnology, vol. 68, no. 2, pp. 151–162, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. M. Baginski, H. Resat, and J. A. McCammon, “Molecular properties of amphotericin B membrane channel: a molecular dynamics simulation,” Molecular Pharmacology, vol. 52, no. 4, pp. 560–570, 1997. View at Google Scholar · View at Scopus
  30. J. Milhaud, V. Ponsinet, M. Takashi, and B. Michels, “Interactions of the drug amphotericin B with phospholipid membranes containing or not ergosterol: new insight into the role of ergosterol,” Biochimica et Biophysica Acta, vol. 1558, no. 2, pp. 95–108, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. M. J. Paquet, I. Fournier, J. Barwicz, P. Tancrède, and M. Auger, “The effects of amphotericin B on pure and ergosterol- or cholesterol-containing dipalmitoylphosphatidylcholine bilayers as viewed by 2H NMR,” Chemistry and Physics of Lipids, vol. 119, no. 1-2, pp. 1–11, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. M. A. Ghannoum and L. B. Rice, “Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance,” Clinical Microbiology Reviews, vol. 12, no. 4, pp. 501–517, 1999. View at Google Scholar · View at Scopus
  33. R. A. Akins, “An update on antifungal targets and mechanisms of resistance in Candida albicans,” Medical Mycology, vol. 43, no. 4, pp. 285–318, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. P. A. Warn, A. Sharp, J. Guinea, and D. W. Denning, “Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Asperigillus and Candida,” The Journal of Antimicrobial Chemotherapy, vol. 53, no. 5, pp. 743–749, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. S. B. Zotchev, “Polyne macrolide antibiotics and their applications in human therapy,” Current Medicinal Chemistry, vol. 10, no. 3, pp. 211–223, 2003. View at Google Scholar · View at Scopus
  36. E. Cevher, D. Sensoy, M. A. M. Taha, and A. Araman, “Effect of thiolated polymers to textural and mucoadhesive properties of vaginal gel Formulations prepared with polycarbophil and chitosan,” AAPS PharmSciTech, vol. 9, no. 3, pp. 953–965, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. J. P. Barrett, K. A. Vardulaki, C. Conlon et al., “A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations,” Clinical Therapeutics, vol. 25, no. 5, pp. 1295–1320, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. D. Ellis, “Amphotericin B: spectrum and resistance,” The Journal of Antimicrobial Chemotherapy, vol. 49, supplement 1, pp. 7–10, 2002. View at Google Scholar
  39. J. A. Maertens, “History of the development of azole derivatives,” Clinical Microbiology and Infection, vol. 10, supplement 1, pp. 1–10, 2004. View at Google Scholar · View at Scopus
  40. A. J. Carrillo-Muñoz, G. Giusiano, P. A. Ezkurra, and G. Quindós, “Antifungal agents: mode of action in yeast cells,” Revista Espanola de Quimioterapia, vol. 19, no. 2, pp. 130–139, 2006. View at Google Scholar
  41. D. W. Woolley, “Some new aspects of the relationship of chemical structure to biological activity,” Science, vol. 100, no. 2609, pp. 579–583, 1944. View at Google Scholar · View at Scopus
  42. R. A. Fromtling, “Overview of medically important antifungal azole derivatives,” Clinical Microbiology Reviews, vol. 1, no. 2, pp. 187–217, 1988. View at Google Scholar · View at Scopus
  43. M. A. Burgess and G. P. Bodey, “Clotrimazole (Bay b 5097): in vitro and clinical pharmacological studies,” Antimicrobial Agents and Chemotherapy, vol. 2, no. 6, pp. 423–426, 1972. View at Google Scholar · View at Scopus
  44. D. Tettenborn, “Toxicity of clotrimazole,” Postgraduate Medical Journal, vol. 50, supplement 1, pp. 17–20, 1974. View at Google Scholar · View at Scopus
  45. R. C. Heel, R. N. Brogden, and G. E. Pakes, “Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections,” Drugs, vol. 19, no. 1, pp. 7–30, 1980. View at Google Scholar · View at Scopus
  46. J. Heeres, L. J. J. Backx, J. H. Mostmans, and J. Van Cutsem, “Antimycotic imidazoles. Part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent,” Journal of Medicinal Chemistry, vol. 22, no. 8, pp. 1003–1005, 1979. View at Google Scholar · View at Scopus
  47. J. W. Van Der Meer, J. J. Keuning, and H. W. Scheijgrond, “The influence of gastric acidity on the bio-availability of ketoconazole,” The Journal of Antimicrobial Chemotherapy, vol. 6, no. 4, pp. 552–554, 1980. View at Google Scholar · View at Scopus
  48. C. Brass, J. N. Galgiani, and T. F. Blaschke, “Disposition of ketoconazole, an oral antifungal, in humans,” Antimicrobial Agents and Chemotherapy, vol. 21, no. 1, pp. 151–158, 1982. View at Google Scholar · View at Scopus
  49. J. R. Perfect, D. T. Durack, J. D. Hamilton, and H. A. Gallis, “Failure of ketoconazole in cryptococcal meningitis,” Journal of the American Medical Association, vol. 247, no. 24, pp. 3349–3351, 1982. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Pont, P. L. Williams, and D. S. Loose, “Ketoconazole blocks adrenal steroid synthesis,” Annals of Internal Medicine, vol. 97, no. 3, pp. 370–372, 1982. View at Google Scholar · View at Scopus
  51. J. H. Lewis, H. J. Zimmerman, G. D. Benson, and K. G. Ishak, “Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases,” Gastroenterology, vol. 86, no. 3, pp. 503–513, 1984. View at Google Scholar · View at Scopus
  52. W. E. Dismukes, G. Cloud, and C. Bowles, “Treatment of blastomycosis and histoplasmosis with ketoconazole: results of a prospective randomized clinical trial,” Annals of Internal Medicine, vol. 103, no. 6, part 1, pp. 861–872, 1985. View at Google Scholar
  53. C. A. Arndt, T. J. Walsh, C. L. McCully, F. M. Balis, P. A. Pizzo, and D. G. Poplack, “Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system,” The Journal of Infectious Diseases, vol. 157, no. 1, pp. 178–180, 1988. View at Google Scholar · View at Scopus
  54. K. W. Brammer, P. R. Farrow, and J. K. Faulkner, “Pharmacokinetics and tissue penetration of fluconazole in humans,” Reviews of Infectious Diseases, vol. 12, supplement 3, pp. S318–S326, 1990. View at Google Scholar · View at Scopus
  55. A. Espinel-Ingroff, S. Shadomy, and R. J. Gebhart, “In vitro studies with R 51,211 (itraconazole),” Antimicrobial Agents and Chemotherapy, vol. 26, no. 1, pp. 5–9, 1984. View at Google Scholar · View at Scopus
  56. C. L. Terrell, “Antifimgal agents. part II. the azoles,” Mayo Clinic Proceedings, vol. 74, no. 1, pp. 78–100, 1999. View at Google Scholar · View at Scopus
  57. J. A. Barone, B. L. Moskovitz, J. Guarnieri et al., “Enhanced bioavailability of itraconazole in hydroxypropyl-β- cyclodextrin solution versus capsules in healthy volunteers,” Antimicrobial Agents and Chemotherapy, vol. 42, no. 7, pp. 1862–1865, 1998. View at Google Scholar · View at Scopus
  58. M. A. Boogaerts, J. Maertens, R. Van der Geest et al., “Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 3, pp. 981–985, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. E. Albengres, H. Le Louët, and J.-P. Tillement, “Systemic antifungal agents. Drug interactions of clinical significance,” Drug Safety, vol. 18, no. 2, pp. 83–97, 1998. View at Publisher · View at Google Scholar
  60. D. W. Denning, K. Venkateswarlu, K. L. Oakley et al., “Itraconazole resistance in Aspergillus fumigatus,” Antimicrobial Agents and Chemotherapy, vol. 41, no. 6, pp. 1364–1368, 1997. View at Google Scholar · View at Scopus
  61. J. A. Sabo and S. M. Abdel-Rahman, “Voriconazole: a new triazole antifungal,” Annals of Pharmacotherapy, vol. 34, no. 9, pp. 1032–1043, 2000. View at Google Scholar · View at Scopus
  62. C. Chiou, A. Groll, and T. Walsh, “New drugs and novel targets for treatment of invasive fungal infections in patients with cancer,” Oncologist, vol. 5, no. 2, pp. 120–135, 2000. View at Google Scholar · View at Scopus
  63. B. A. Potoski and J. Brown, “The safety of voriconazole,” Clinical Infectious Diseases, vol. 35, no. 10, pp. 1273–1275, 2002. View at Publisher · View at Google Scholar · View at PubMed
  64. D. W. Denning, “Echinocandins: a new class of antifungal,” The Journal of Antimicrobial Chemotherapy, vol. 49, no. 6, pp. 889–891, 2002. View at Google Scholar · View at Scopus
  65. M. Kurtz and C. Douglas, “Lipopeptide inhibitors of fungal glucan synthase,” Journal of Medical and Veterinary Mycology, vol. 35, no. 2, pp. 79–86, 1997. View at Google Scholar · View at Scopus
  66. F. Marco, M. A. Pfaller, S. A. Messer, and R. N. Jones, “Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi,” Medical Mycology, vol. 36, no. 6, pp. 433–436, 1998. View at Google Scholar · View at Scopus
  67. P. Mazur, N. Morin, W. Baginsky et al., “Differential expression and function of two homologous subunits of yeast 1,3-β-D-glucan synthase,” Molecular and Cellular Biology, vol. 15, no. 10, pp. 5671–5681, 1995. View at Google Scholar · View at Scopus
  68. N. H. Georgopapadakou and J. S. Tkacz, “The fungal cell wall as a drug target,” Trends in Microbiology, vol. 3, no. 3, pp. 98–104, 1995. View at Publisher · View at Google Scholar · View at Scopus
  69. E. A. Stone, H. B. Fung, and H. L. Kirschenbaum, “Caspofungin: an echinocandin antifungal agent,” Clinical Therapeutics, vol. 24, no. 3, pp. 351–377, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. S. P. Franzot and A. Casadevall, “Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro,” Antimicrobial Agents and Chemotherapy, vol. 41, no. 2, pp. 331–336, 1997. View at Google Scholar · View at Scopus
  71. M. A. Pfaller, S. A. Messer, S. Gee et al., “In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents,” Journal of Clinical Microbiology, vol. 37, no. 3, pp. 870–872, 1999. View at Google Scholar · View at Scopus
  72. A. Espinel-Ingroff, “Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts,” Journal of Clinical Microbiology, vol. 36, no. 10, pp. 2950–2956, 1998. View at Google Scholar · View at Scopus
  73. K. L. Oakley, C. B. Moore, and D. W. Denning, “In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp,” Antimicrobial Agents and Chemotherapy, vol. 42, no. 10, pp. 2726–2730, 1998. View at Google Scholar · View at Scopus
  74. M. W. Pound, M. L. Townsend, and R. H. Drew, “Echinocandin pharmacodynamics: review and clinical implications,” The Journal of Antimicrobial Chemotherapy, vol. 65, no. 6, Article ID dkq081, pp. 1108–1118, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. M. Feldmesser, Y. Kress, A. Mednick, and A. Casadevall, “The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans,” The Journal of Infectious Diseases, vol. 182, no. 6, pp. 1791–1795, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. D. Cappelletty and K. Eiselstein-McKitrick, “The echinocandins,” Pharmacotherapy, vol. 27, no. 3, pp. 369–388, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. R. F. Hector, “Compounds active against cell walls of medically important fungi,” Clinical Microbiology Reviews, vol. 6, no. 1, pp. 1–21, 1993. View at Google Scholar · View at Scopus
  78. M. Niewerth, D. Kunze, M. Seibold, M. Schaller, H. C. Korting, and B. Hube, “Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors,” Antimicrobial Agents and Chemotherapy, vol. 47, no. 6, pp. 1805–1817, 2003. View at Publisher · View at Google Scholar · View at Scopus
  79. S. H. Leem, J. E. Park, I. S. Kim, J. Y. Chae, A. Sugino, and Y. Sunwoo, “The possible mechanism of action of ciclopirox olamine in the yeast Saccharomyces cerevisiae,” Molecules and Cells, vol. 15, no. 1, pp. 55–61, 2003. View at Google Scholar · View at Scopus
  80. M. Borgers, “Mechanism of action of antifungal drugs, with special reference to the imidazole derivatives,” Reviews of Infectious Diseases, vol. 2, no. 4, pp. 520–534, 1980. View at Google Scholar · View at Scopus
  81. M. Pfaller, G. J. Moet, S. A. Messer, R. N. Jones, and M. Castanheira, “Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: Report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009),” Journal of Clinical Microbiology, vol. 49, no. 1, pp. 396–399, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. M. A. Pfaller, G. J. Moet, S. A. Messer, R. N. Jones, and M. Castanheira, “Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 2, pp. 561–566, 2011. View at Publisher · View at Google Scholar · View at PubMed
  83. M. A. Pfaller, S. A. Messer, G. J. Moet, R. N. Jones, and M. Castanheira, “Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009),” International Journal of Antimicrobial Agents, vol. 38, no. 1, pp. 65–69, 2011. View at Publisher · View at Google Scholar · View at PubMed
  84. S. Normark and J. Schönebeck, “In vitro studies of 5-fluorocytosine resistance in Candida albicans and Torulopsis glabrata,” Antimicrobial Agents and Chemotherapy, vol. 2, no. 3, pp. 114–121, 1972. View at Google Scholar · View at Scopus
  85. G. Medoff and G. S. Kobayashi, “Strategies in the treatment of systemic fungal infections,” New England Journal of Medicine, vol. 302, no. 3, pp. 145–155, 1980. View at Google Scholar · View at Scopus
  86. Z. A. Kanafani and J. R. Perfect, “Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact,” Clinical Infectious Diseases, vol. 46, no. 1, pp. 120–128, 2008. View at Publisher · View at Google Scholar · View at PubMed
  87. M. A. Pfaller and W. L. Yu, “Antifungal susceptibility testing: new technology and clinical applications,” Infectious Disease Clinics of North America, vol. 15, no. 4, pp. 1227–1261, 2001. View at Publisher · View at Google Scholar · View at Scopus
  88. W. Powderly, G. S. Kobayashi, G. P. Herzig, and G. Medoff, “Amphotericin B-resistant yeast infection in severely immunocompromised patients,” American Journal of Medicine, vol. 84, no. 5, pp. 826–832, 1988. View at Google Scholar · View at Scopus
  89. E. Anaissie, N. C. Karyotakis, R. Hachem, M. C. Dignani, J. H. Rex, and V. Paetznick, “Correlation between in vitro and in vivo activity of antifungal agents against Candida species,” The Journal of Infectious Diseases, vol. 170, no. 2, pp. 384–389, 1994. View at Google Scholar · View at Scopus
  90. T. White, K. Marr, and R. Bowden, “Clinical, cellular, and molecular factors that contribute to antifungal drug resistance,” Clinical Microbiology Reviews, vol. 11, no. 2, pp. 382–402, 1998. View at Google Scholar · View at Scopus
  91. S. Perea and T. Patterson, “Antifungal resistance in pathogenic fungi,” Clinical Infectious Diseases, vol. 35, no. 9, pp. 1073–1080, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  92. A. Espinel-Ingroff, “Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi,” Revista Iberoamericana de Micologia, vol. 25, no. 2, pp. 101–106, 2008. View at Google Scholar · View at Scopus
  93. A. Espinel-Ingroff, “In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature,” Revista Iberoamericana de Micologia, vol. 20, no. 4, pp. 121–136, 2003. View at Google Scholar · View at Scopus
  94. M. Pfaller, L. Boyken, R. J. Hollis et al., “In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance,” Journal of Clinical Microbiology, vol. 46, no. 1, pp. 150–156, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  95. M. Maligie and C. Selitrennikoff, “Cryptococcus neoformans resistance to echinocandins: (1,3)β-glucan synthase activity is sensitive to echinocandins,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 7, pp. 2851–2856, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  96. CLSI, C.a.L.S.I., Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard—Third Edition—Document M27-A3, CLSI, Wayne, Pa, USA, 2008.
  97. CLSI, C.a.L.S.I., Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous fungi; Approved Standard—Second Edition—Document M38-A2, CLSI, Wayne, Pa, USA, 2008.
  98. J. L. Rodríguez-Tudela, M. C. Arendrup, M. Cuenca-Estrella, J. P. Donnelly, and C. Lass-Flörl, “EUCAST breakpoints for antifungals,” Drug News and Perspectives, vol. 23, no. 2, pp. 93–97, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  99. M. A. Pfaller, D. J. Diekema, D. Andes et al., “Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria,” Drug Resistance Updates, vol. 14, no. 3, pp. 164–176, 2011. View at Publisher · View at Google Scholar · View at PubMed
  100. M. A. Pfaller, M. Castanheira, S. A. Messer, G. J. Moet, and R. N. Jones, “Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009),” Diagnostic Microbiology and Infectious Disease, vol. 69, no. 1, pp. 45–50, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  101. D. Sanglard, “Clinical relevance of mechanisms of antifungal drug resistance in yeasts,” Enfermedades Infecciosas y Microbiologia Clinica, vol. 20, no. 9, pp. 462–479, 2002. View at Google Scholar
  102. D. Sanglard, F. Ischer, D. Calabrese, M. D. Micheli, and J. Bille, “Multiple resistance mechanisms to azole antifungals in yeast clinical isolates,” Drug Resistance Updates, vol. 1, no. 4, pp. 255–265, 1998. View at Publisher · View at Google Scholar · View at Scopus
  103. S. Perea, J. L. López-Ribot, W. R. Kirkpatrick et al., “Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 10, pp. 2676–2684, 2001. View at Publisher · View at Google Scholar · View at PubMed
  104. D. M. MacCallum, A. Coste, F. Ischer, M. D. Jacobsen, F. C. Odds, and D. Sanglard, “Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 4, pp. 1476–1483, 2010. View at Publisher · View at Google Scholar · View at PubMed
  105. R. Franz, S. L. Kelly, D. C. Lamb, D. E. Kelly, M. Ruhnke, and J. Morschhäuser, “Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains,” Antimicrobial Agents and Chemotherapy, vol. 42, no. 12, pp. 3065–3072, 1998. View at Google Scholar
  106. K. A. Marr, C. N. Lyons, T. Rustad, R. A. Bowden, and T. C. White, “Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR,” Antimicrobial Agents and Chemotherapy, vol. 42, no. 10, pp. 2584–2589, 1998. View at Google Scholar
  107. M. de Micheli, J. Bille, C. Schueller, and D. Sanglard, “A common drug-responsive element mediates the upregulation of the Candida albicans ABC transporters CDR1 and CDR2, two genes involved in antifungal drug resistance,” Molecular Microbiology, vol. 43, no. 5, pp. 1197–1214, 2002. View at Publisher · View at Google Scholar · View at Scopus
  108. N. Kamani, N. Akhtar Gaur, S. Jha et al., “SRE1 and SRE2 are two specific steroid-responsive modules of Candida drug resistance gene I (CDRI) promoter,” Yeast, vol. 21, no. 3, pp. 219–239, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  109. N. Puri, S. Krishnamurthy, S. Habib, S. E. Hasnain, S. K. Goswami, and R. Prasad, “CDR1, a multidrug resistance gene from Candida albicans, contains multiple regulatory domains in its promoter and the distal AP-1 element mediates its induction by miconazole,” FEMS Microbiology Letters, vol. 180, no. 2, pp. 213–219, 1999. View at Publisher · View at Google Scholar · View at Scopus
  110. N. Gaur, R. Manoharlal, P. Saini et al., “Expression of the CDR1 efflux pump in clinical Candida albicans isolates is controlled by a negative regulatory element,” Biochemical and Biophysical Research Communications, vol. 332, no. 1, pp. 206–214, 2005. View at Publisher · View at Google Scholar · View at PubMed
  111. N. A. Gaur, N. Puri, N. Karnani, G. Mukhopadhyay, S. K. Goswami, and R. Prasad, “Identification of a negative regulatory element which regulates basal transcription of a multidrug resistance gene CDR1 of Candida albicans,” FEMS Yeast Research, vol. 4, no. 4-5, pp. 389–399, 2004. View at Publisher · View at Google Scholar · View at Scopus
  112. A. T. Coste, J. Crittin, C. Bauser, B. Rohde, and D. Sanglard, “Functional analysis of cis-and trans-acting elements of the Candida albicans CDR2 promoter with a novel promoter reporter system,” Eukaryotic Cell, vol. 8, no. 8, pp. 1250–1267, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  113. T. T. Liu, S. Znaidi, K. S. Barker et al., “Genome-wide expression and location analyses of the Candida albicans Tac1p regulon,” Eukaryotic Cell, vol. 6, no. 11, pp. 2122–2138, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  114. J. E. Bennett, K. Izumikawa, and K. A. Marr, “Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 5, pp. 1773–1777, 2004. View at Publisher · View at Google Scholar
  115. K. Izumikawa, H. Kakeya, H. F. Tsai, B. Grimberg, and J. E. Bennett, “Function of Candida glabrata ABC transporter gene, PDH1,” Yeast, vol. 20, no. 3, pp. 249–261, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  116. D. Sanglard, F. Ischer, and J. Bille, “Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 4, pp. 1174–1183, 2001. View at Publisher · View at Google Scholar · View at PubMed
  117. D. Sanglard, F. Ischer, D. Calabrese, P. A. Majcherczyk, and J. Bille, “The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents,” Antimicrobial Agents and Chemotherapy, vol. 43, no. 11, pp. 2753–2765, 1999. View at Google Scholar
  118. R. Torelli, B. Posteraro, S. Ferrari et al., “The ATP-binding cassette transporter-encoding gene CgSNQ2 is contributing to the CgPDR1-dependent azole resistance of Candida glabrata,” Molecular Microbiology, vol. 68, no. 1, pp. 186–201, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  119. J. P. Vermitsky, K. D. Earhart, W. L. Smith, R. Homayouni, T. D. Edlind, and P. D. Rogers, “Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome-wide expression studies,” Molecular Microbiology, vol. 61, no. 3, pp. 704–722, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  120. J. -P. Vermitsky and T. D. Edlind, “Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 10, pp. 3773–3781, 2004. View at Publisher · View at Google Scholar · View at PubMed
  121. S. Tsao, F. Rahkhoodaee, and M. Raymond, “Relative contributions of the Candida albicans ABC transporters Cdrlp and Cdr2p to clinical azole resistance,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 4, pp. 1344–1352, 2009. View at Publisher · View at Google Scholar · View at PubMed
  122. A. Holmes, Y. -H. Lin, K. Niimi et al., “ABC transporter Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant Candida albicans clinical isolates,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 11, pp. 3851–3862, 2008. View at Publisher · View at Google Scholar · View at PubMed
  123. S. Ferrari, M. Sanguinetti, R. Torelli, B. Posteraro, and D. Sanglard, “Contribution of CgPDR1-regulated genes in enhanced virulence of azole-resistant Candida glabrata,” PLoS One, vol. 6, no. 3, Article ID e17589, 2011. View at Publisher · View at Google Scholar · View at PubMed
  124. G. Moran, D. Sullivan, J. Morschhäuser, and D. Coleman, “The Candida dubliniensis CdCDR1 gene is not essential for fluconazole resistance,” Antimicrobial Agents and Chemotherapy, vol. 46, no. 9, pp. 2829–2841, 2002. View at Publisher · View at Google Scholar
  125. G. P. Moran, D. Sanglard, S. M. Donnelly, D. B. Shanley, D. J. Sullivan, and D. C. Coleman, “Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis,” Antimicrobial Agents and Chemotherapy, vol. 42, no. 7, pp. 1819–1830, 1998. View at Google Scholar
  126. E. Lamping, A. Ranchod, K. Nakamura et al., “Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 2, pp. 354–369, 2009. View at Publisher · View at Google Scholar · View at PubMed
  127. S. Katiyar and T. Edlind, “Identification and expression of multidrug resistance-related ABC transporter genes in Candida krusei,” Medical Mycology, vol. 39, no. 1, pp. 109–116, 2001. View at Google Scholar · View at Scopus
  128. A. M. Nascimento, G. H. Goldman, S. Park et al., “Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole,” Antimicrobial Agents and Chemotherapy, vol. 47, no. 5, pp. 1719–1726, 2003. View at Publisher · View at Google Scholar
  129. J. Slaven, M. Anderson, D. Sanglard et al., “Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate,” Fungal Genetics and Biology, vol. 36, no. 3, pp. 199–206, 2002. View at Publisher · View at Google Scholar · View at Scopus
  130. J. W. Slaven et al., “Induced expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in response to itraconazole,” Fungal Genetics and Biology, vol. 36, pp. 199–206, 2002. View at Google Scholar
  131. C. P. Semighini, M. Marins, M. H. S. Goldman, and G. H. Goldman, “Quantitative analysis of the relative transcript levels of ABC transporter Atr genes in Aspergillus nidulans by real-time reverse transcription-PCR assay,” Applied and Environmental Microbiology, vol. 68, no. 3, pp. 1351–1357, 2002. View at Publisher · View at Google Scholar · View at Scopus
  132. A. M. do Nascimento, M. H. Goldman, and G. H. Goldman, “Molecular characterization of ABC transporter-encoding genes in Aspergillus nidulans,” Genetics and Molecular Research, vol. 1, no. 4, pp. 337–349, 2002. View at Google Scholar · View at Scopus
  133. S. Schubert, P. Rogers, and J. Morschhäuser, “Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 12, pp. 4274–4280, 2008. View at Publisher · View at Google Scholar · View at PubMed
  134. C. Heilmann, S. Schneider, K. S. Barker, P. D. Rogers, and J. Morschhäuser, “An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicans,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 1, pp. 353–359, 2010. View at Publisher · View at Google Scholar · View at PubMed
  135. F. Morio, C. Loge, B. Besse, C. Hennequin, and P. Le Pape, “Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature,” Diagnostic Microbiology and Infectious Disease, vol. 66, no. 4, pp. 373–384, 2010. View at Publisher · View at Google Scholar · View at PubMed
  136. D. S. Perlin, “Resistance to echinocandin-class antifungal drugs,” Drug Resistance Updates, vol. 10, no. 3, pp. 121–130, 2007. View at Publisher · View at Google Scholar · View at PubMed
  137. W. W. Hope, L. Tabernero, D. W. Denning, and M. J. Anderson, “Molecular mechanisms of primary resistance to flucytosine in Candida albicans,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 11, pp. 4377–4386, 2004. View at Publisher · View at Google Scholar · View at PubMed
  138. V. Fardeau, G. Lelandais, A. Oldfield et al., “The central role of PDR1 in the foundation of yeast drug resistance,” Journal of Biological Chemistry, vol. 282, no. 7, pp. 5063–5074, 2007. View at Publisher · View at Google Scholar · View at PubMed
  139. S. Le Crom, F. Devaux, P. Marc, X. Zhang, W. S. Moye-Rowley, and C. Jacq, “New insights into the pleiotropic drug resistance network from genome-wide characterization of the YRR1 transcription factor regulation system,” Molecular and Cellular Biology, vol. 22, no. 8, pp. 2642–2649, 2002. View at Publisher · View at Google Scholar
  140. A. Delahodde, T. Delaveau, and C. Jacq, “Positive autoregulation of the yeast transcription factor Pdr3p, which is involved in control of drug resistance,” Molecular and Cellular Biology, vol. 15, no. 8, pp. 4043–4051, 1995. View at Google Scholar
  141. D. Katzmann, P. E. Burnett, J. Golin, Y. Mahe, and W. S. Moye-Rowley, “Transcriptional control of the yeast PDR5 gene by the PDR3 gene product,” Molecular and Cellular Biology, vol. 14, no. 7, pp. 4653–4661, 1994. View at Google Scholar
  142. Y. Mamnun, R. Pandjaitan, Y. Mahé, A. Delahodde, and K. Kuchler, “The yeast zinc finger regulators Pdr1p and Pdr3p control pleiotropic drug resistance (PDR) as homo- and heterodimers in vivo,” Molecular Microbiology, vol. 46, no. 5, pp. 1429–1440, 2002. View at Publisher · View at Google Scholar
  143. H. Tsai, A. A. Krol, K. E. Sarti, and J. E. Bennett, “Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 4, pp. 1384–1392, 2006. View at Publisher · View at Google Scholar · View at PubMed
  144. J. P. Vermitsky, K. D. Earhart, W. L. Smith, R. Homayouni, T. D. Edlind, and P. D. Rogers, “Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome-wide expression studies,” Molecular Microbiology, vol. 61, no. 3, pp. 704–722, 2006. View at Publisher · View at Google Scholar · View at PubMed
  145. S. Ferrari, F. Ischer, D. Calabrese et al., “Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence,” PLoS Pathogens, vol. 5, no. 1, Article ID e1000268, 2009. View at Publisher · View at Google Scholar · View at PubMed
  146. H.-F. Tsai, A. A. Krol, K. E. Sarti, and J. E. Bennett, “Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 4, pp. 1384–1392, 2006. View at Publisher · View at Google Scholar · View at PubMed
  147. H. Shen, M. M. An, D. J. Wang et al., “Fcr1p inhibits development of fluconazole resistance in Candida albicans by abolishing CDR1 induction,” Biological and Pharmaceutical Bulletin, vol. 30, no. 1, pp. 68–73, 2007. View at Publisher · View at Google Scholar
  148. D. Talibi and M. Raymond, “Isolation of a putative Candida albicans transcriptional regulator involved in pleiotropic drug resistance by functional complementation of a pdr1 pdr3 mutation in Saccharomyces cerevisiae,” Journal of Bacteriology, vol. 181, no. 1, pp. 231–240, 1999. View at Google Scholar
  149. X. Yang, D. Talibi, S. Weber, G. Poisson, and M. Raymond, “Functional isolation of the Candida albicans FCR3 gene encoding a bZip transcription factor homologous to Saccharomyces cerevisiae Yap3p,” Yeast, vol. 18, no. 13, pp. 1217–1225, 2001. View at Publisher · View at Google Scholar · View at PubMed
  150. A. T. Coste, M. Ramsdale, F. Ischer, and D. Sanglard, “Divergent functions of three Candida albicans zinc-cluster transcription factors (CTA4, ASG1 and CTF1) complementing pleiotropic drug resistance in Saccharomyces cerevisiae,” Microbiology, vol. 154, no. 5, pp. 1491–1501, 2008. View at Publisher · View at Google Scholar · View at PubMed
  151. C. -G. Chen, Y. -L. Yang, H. -I. Shih, C. -L. Su, and H. -J. Lo, “CaNdt80 is involved in drug resistance in Candida albicans by regulating CDR1,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 12, pp. 4505–4512, 2004. View at Publisher · View at Google Scholar · View at PubMed
  152. J. Wang, Y. L. Yang, C. J. Wu et al., “The DNA-binding domain of CaNdt80p is required to activate CDR1 involved in drug resistance in Candida albicans,” Journal of Medical Microbiology, vol. 55, no. 10, pp. 1403–1411, 2006. View at Publisher · View at Google Scholar · View at PubMed
  153. A. Sellam, F. Tebbji, and A. Nantel, “Role of Ndt80p in sterol metabolism regulation and azole resistance in Candida albicans,” Eukaryotic Cell, vol. 8, no. 8, pp. 1174–1183, 2009. View at Publisher · View at Google Scholar · View at PubMed
  154. I. Hikkel, A. Lucau-Danila, T. Delaveau, P. Marc, F. Devaux, and C. Jacq, “A general strategy to uncover transcription factor properties identifies a new regulator of drug resistance in yeast,” Journal of Biological Chemistry, vol. 278, no. 13, pp. 11427–11432, 2003. View at Publisher · View at Google Scholar · View at PubMed
  155. A. Kren, Y. M. Mamnun, B. E. Bauer et al., “War1p, a novel transcription factor controlling weak acid stress response in yeast,” Molecular and Cellular Biology, vol. 23, no. 5, pp. 1775–1785, 2003. View at Publisher · View at Google Scholar
  156. I. Mendizabal, G. Rios, J. M. Mulet, R. Serrano, and I. F. De Larrinoa, “Yeast putative transcription factors involved in salt tolerance,” FEBS Letters, vol. 425, no. 2, pp. 323–328, 1998. View at Publisher · View at Google Scholar
  157. P. Schjerling and S. Holmberg, “Comparative amino acid sequence analysis of the C6 zinc cluster family of transcriptional regulators,” Nucleic Acids Research, vol. 24, no. 23, pp. 4599–4607, 1996. View at Google Scholar
  158. A. T. Coste, M. Karababa, F. Ischer, J. Bille, and D. Sanglard, “TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2,” Eukaryotic Cell, vol. 3, no. 6, pp. 1639–1652, 2004. View at Publisher · View at Google Scholar · View at PubMed
  159. T. Rustad, D. A. Stevens, M. A. Pfaller, and T. C. White, “Homozygosity at the Candida albicans MTL locus associated with azole resistance,” Microbiology, vol. 148, no. 4, pp. 1061–1072, 2002. View at Google Scholar
  160. A. Coste, A. Selmecki, A. Forche et al., “Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates,” Eukaryotic Cell, vol. 6, no. 10, pp. 1889–1904, 2007. View at Publisher · View at Google Scholar · View at PubMed
  161. A. Coste, V. Turner, F. Ischer et al., “A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans,” Genetics, vol. 172, no. 4, pp. 2139–2156, 2006. View at Publisher · View at Google Scholar · View at PubMed
  162. A. Selmecki, A. Forche, and J. Berman, “Aneuploidy and isochromosome formation in drug-resistant Candida albicans,” Science, vol. 313, no. 5785, pp. 367–370, 2006. View at Publisher · View at Google Scholar · View at PubMed
  163. A. Selmecki, M. Gerami-Nejad, C. Paulson, A. Forche, and J. Berman, “An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1,” Molecular Microbiology, vol. 68, no. 3, pp. 624–641, 2008. View at Publisher · View at Google Scholar · View at PubMed
  164. W. Wu, C. Pujol, S. R. Lockhart, and D. R. Soll, “Chromosome loss followed by duplication is the major mechanism of spontaneous mating-type locus homozygosis in Candida albicans,” Genetics, vol. 169, no. 3, pp. 1311–1327, 2005. View at Publisher · View at Google Scholar · View at PubMed
  165. M. Fling, J. Kopf, A. Tamarkin, J. A. Gorman, H. A. Smith, and Y. Koltin, “Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate,” Molecular and General Genetics, vol. 227, no. 2, pp. 318–329, 1991. View at Google Scholar
  166. R. Ben-Yaacov, S. Knoller, G. A. Caldwell, J. M. Becker, and Y. Koltin, “Candida albicans gene encoding resistance to benomyl and methotrexate is a multidrug resistance gene,” Antimicrobial Agents and Chemotherapy, vol. 38, no. 4, pp. 648–652, 1994. View at Google Scholar
  167. P. Vandeputte, G. Larcher, T. Bergès, G. Renier, D. Chabasse, and J. -P. Bouchara, “Mechanisms of azole resistance in a clinical isolate of Candida tropicalis,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 11, pp. 4608–4615, 2005. View at Publisher · View at Google Scholar · View at PubMed
  168. E. Pinjon, C. J. Jackson, S. L. Kelly et al., “Reduced azole susceptibility in genotype 3 Candida dubliniensis isolates associated with increased CaCDR1 and CdCDR2 expression,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 4, pp. 1312–1318, 2005. View at Publisher · View at Google Scholar · View at PubMed
  169. E. Pinjon, G. P. Moran, C. J. Jackson et al., “Molecular mechanisms of itraconazole resistance in Candida dubliniensis,” Antimicrobial Agents and Chemotherapy, vol. 47, no. 8, pp. 2424–2437, 2003. View at Publisher · View at Google Scholar
  170. S. Wirsching, G. P. Moran, D. J. Sullivan, D. C. Coleman, and J. Morschhäuser, “MDR1-mediated drug resistance in Candida dubliniensis,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 12, pp. 3416–3421, 2001. View at Publisher · View at Google Scholar · View at PubMed
  171. P. Riggle and C. Kumamoto, “Transcriptional regulation of MDR1, encoding a drug efflux determinant, in fluconazole-resistant Candida albicans strains through an Mcm1p binding site,” Eukaryotic Cell, vol. 5, no. 12, pp. 1957–1968, 2006. View at Publisher · View at Google Scholar · View at PubMed
  172. B. Rognon, Z. Kozovska, A. T. Coste, G. Pardini, and D. Sanglard, “Identification of promoter elements responsible for the regulation of MDR1 from Candida albicans, a major facilitator transporter involved in azole resistance,” Microbiology, vol. 152, no. 12, pp. 3701–3722, 2006. View at Publisher · View at Google Scholar · View at PubMed
  173. D. Nguyên, A. Alarco, and M. Raymond, “Multiple Yap1p-binding sites mediate induction of the yeast major facilitator FLR1 gene in response to drugs, oxidants, and alkylating agents,” Journal of Biological Chemistry, vol. 276, no. 2, pp. 1138–1145, 2001. View at Publisher · View at Google Scholar · View at PubMed
  174. D. Hiller, S. Stahl, and J. Morschhäuser, “Multiple cis-acting sequences mediate upregulation of the MDR1 efflux pump in a fluconazole-resistant clinical Candida albicans isolate,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 7, pp. 2300–2308, 2006. View at Publisher · View at Google Scholar · View at PubMed
  175. A. M. Alarco and M. Raymond, “The bZip transcription factor Cap1p is involved in multidrug resistance and oxidative stress response in Candida albicans,” Journal of Bacteriology, vol. 181, no. 3, pp. 700–708, 1999. View at Google Scholar
  176. X. Zhang, M. De Micheli, S. T. Coleman, D. Sanglard, and W. S. Moye-Rowley, “Analysis of the oxidative stress regulation of the Candida albicans transcription factor, Cap1p,” Molecular Microbiology, vol. 36, no. 3, pp. 618–629, 2000. View at Publisher · View at Google Scholar
  177. S. Znaidi, K. S. Barker, S. Weber et al., “Identification of the Candida albicans Cap1p regulon,” Eukaryotic Cell, vol. 8, no. 6, pp. 806–820, 2009. View at Publisher · View at Google Scholar · View at PubMed
  178. N. Dunkel, J. Blaß, P. D. Rogers, and J. Morschhäuser, “Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains,” Molecular Microbiology, vol. 69, no. 4, pp. 827–840, 2008. View at Publisher · View at Google Scholar · View at PubMed
  179. J. Morschhäuser, K. S. Barker, T. T. Liu, J. BlaB-Warmuth, R. Homayouni, and P. D. Rogers, “The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans,” PLoS Pathogens, vol. 3, no. 11, Article ID e164, 2007. View at Publisher · View at Google Scholar · View at PubMed
  180. N. Dunkel, T. T. Liu, K. S. Barker, R. Homayouni, J. Morschhäuser, and P. D. Rogers, “A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate,” Eukaryotic Cell, vol. 7, no. 7, pp. 1180–1190, 2008. View at Publisher · View at Google Scholar · View at PubMed
  181. S. Znaidi, S. Weber, O. Z. Al-Abdin et al., “Genomewide location analysis of Candida albicans Upc2p, a regulator of sterol metabolism and azole drug resistance,” Eukaryotic Cell, vol. 7, no. 5, pp. 836–847, 2008. View at Publisher · View at Google Scholar · View at PubMed
  182. S. Mogavero, A. Tavanti, S. Senesi, P. D. Rogers, and J. Morschhäuser, “Differential requirement of the transcription factor Mcm1 for activation of the Candida albicans multidrug efflux pump MDR1 by its regulators Mrr1 and Cap1,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 5, pp. 2061–2066, 2011. View at Publisher · View at Google Scholar · View at PubMed
  183. S. Schubert, K. S. Barker, S. Znaidi et al., “Regulation of efflux pump expression and drug resistance by the transcription factors Mrr1, Upc2, and Cap1 in Candida albicans,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 5, pp. 2212–2223, 2011. View at Publisher · View at Google Scholar · View at PubMed
  184. H. Vanden Bossche, P. Marichal, J. Gorrens, D. Bellens, H. Moereels, and P. A. J. Janssen, “Mutation in cytochrome P-450-dependent 14α-demethylase results in decreased affinity for azole antifungals,” Biochemical Society Transactions, vol. 18, no. 1, pp. 56–59, 1990. View at Google Scholar
  185. P. Marichal, L. Koymans, S. Willemsens et al., “Contribution of mutations in the cytochrome P450 14α-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans,” Microbiology, vol. 145, no. 10, pp. 2701–2713, 1999. View at Google Scholar
  186. D. C. Lamb, A. Corran, B. C. Baldwin, J. Kwon-Chung, and S. L. Kelly, “Resistant P45051A1 activity in azole antifungal tolerant Cryptococcus neoformans from AIDS patients,” FEBS Letters, vol. 368, no. 2, pp. 326–330, 1995. View at Publisher · View at Google Scholar
  187. D. Sanglard, F. Ischer, L. Koymans, and J. Bille, “Amino acid substitutions in the cytochrome P-450 lanosterol 14α- demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents,” Antimicrobial Agents and Chemotherapy, vol. 42, no. 2, pp. 241–253, 1998. View at Google Scholar
  188. E. Mellado, G. Garcia-Effron, L. Alcazar-Fuoli, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela, “Substitutions at methionine 220 in the 14α-sterol demethylase (cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 7, pp. 2747–2750, 2004. View at Publisher · View at Google Scholar · View at PubMed
  189. J. Chen, H. Li, R. Li, D. Bu, and Z. Wan, “Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma,” The Journal of Antimicrobial Chemotherapy, vol. 55, no. 1, pp. 31–37, 2005. View at Publisher · View at Google Scholar · View at PubMed
  190. T. M. Diaz-Guerra, E. Mellado, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela, “A point mutation in the 14α-sterol demethylase gene cyp51a contributes to itraconazole resistance in Aspergillus fumigatus,” Antimicrobial Agents and Chemotherapy, vol. 47, no. 3, pp. 1120–1224, 2003. View at Publisher · View at Google Scholar
  191. P. A. Mann, R. M. Parmegiani, S. Q. Wei et al., “Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14α-demethylase,” Antimicrobial Agents and Chemotherapy, vol. 47, no. 2, pp. 577–581, 2003. View at Publisher · View at Google Scholar
  192. E. Mellado, G. Garcia-Effron, L. Alcázar-Fuoli et al., “A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 6, pp. 1897–1904, 2007. View at Publisher · View at Google Scholar · View at PubMed
  193. P. E. Verweij, E. Snelders, G. H. Kema, E. Mellado, and W. J. Melchers, “Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?” The Lancet Infectious Diseases, vol. 9, no. 12, pp. 789–795, 2009. View at Publisher · View at Google Scholar
  194. E. Snelders, R. A. G. Huis In't Veld, A. J. M. M. Rijs, G. H. J. Kema, W. J. G. Melchers, and P. E. Verweij, “Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles,” Applied and Environmental Microbiology, vol. 75, no. 12, pp. 4053–4057, 2009. View at Publisher · View at Google Scholar · View at PubMed
  195. K. L. Mortensen, E. Mellado, C. Lass-Flörl, J. L. Rodriguez-Tudela, H. K. Johansen, and M. C. Arendrup, “Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 11, pp. 4545–4549, 2010. View at Publisher · View at Google Scholar · View at PubMed
  196. S. Park, R. Kelly, J. N. Kahn et al., “Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 8, pp. 3264–3273, 2005. View at Publisher · View at Google Scholar · View at PubMed
  197. S. V. Balashov, S. Park, and D. S. Perlin, “Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 6, pp. 2058–2063, 2006. View at Publisher · View at Google Scholar · View at PubMed
  198. G. Garcia-Effron, S. Park, and D. S. Perlin, “Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 1, pp. 112–122, 2009. View at Publisher · View at Google Scholar · View at PubMed
  199. S. Katiyar, M. Pfaller, and T. Edlind, “Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 8, pp. 2892–2894, 2006. View at Publisher · View at Google Scholar · View at PubMed
  200. J. Kahn, G. Garcia-Effron, M. -J. Hsu, S. Park, K. A. Marr, and D. S. Perlin, “Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 5, pp. 1876–1878, 2007. View at Publisher · View at Google Scholar · View at PubMed
  201. M. E. Johnson, S. K. Katiyar, and T. D. Edlind, “New Fks hot spot for acquired echinocandin resistance in Saccharomyces cerevisiae and its contribution to intrinsic resistance of Scedosporium species,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 8, pp. 3774–3781, 2011. View at Publisher · View at Google Scholar · View at PubMed
  202. R. E. Gardiner, P. Souteropoulos, S. Park, and D. S. Perlin, “Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin,” Medical Mycology, vol. 43, supplement 1, pp. S299–S305, 2005. View at Publisher · View at Google Scholar
  203. E. Rocha, G. Garcia-Effron, S. Park, and D. S. Perlin, “A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 11, pp. 4174–4176, 2007. View at Publisher · View at Google Scholar · View at PubMed
  204. D. Kerridge, M. Fasoli, and F. J. Wayman, “Drug resistance in Candida albicans and Candida glabrata,” Annals of the New York Academy of Sciences, vol. 544, pp. 245–259, 1988. View at Google Scholar
  205. P. Vandeputte, L. Pineau, G. Larcher et al., “Molecular mechanisms of resistance to 5-fluorocytosine in laboratory mutants of Candida glabrata,” Mycopathologia, vol. 171, no. 1, pp. 11–21, 2011. View at Publisher · View at Google Scholar · View at PubMed
  206. T. D. Edlind and S. K. Katiyar, “Mutational analysis of flucytosine resistance in Candida glabrata,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 11, pp. 4733–4738, 2010. View at Publisher · View at Google Scholar · View at PubMed
  207. T. P. Ko, J. J. Lin, C. Y. Hu, Y. H. Hsu, A. H. J. Wang, and S. H. Liaw, “Crystal structure of yeast cytosine deaminase: insights into enzyme mechanism and evolution,” Journal of Biological Chemistry, vol. 278, no. 21, pp. 19111–19117, 2003. View at Publisher · View at Google Scholar · View at PubMed
  208. K. Henry, J. Nickels, and T. Edlind, “Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors,” Antimicrobial Agents and Chemotherapy, vol. 44, no. 10, pp. 2693–2700, 2000. View at Publisher · View at Google Scholar
  209. M. A. Ribeiro and C. R. Paula, “Up-regulation of ERG11 gene among fluconazole-resistant Candida albicans generated in vitro: is there any clinical implication?” Diagnostic Microbiology and Infectious Disease, vol. 57, no. 1, pp. 71–75, 2007. View at Publisher · View at Google Scholar · View at PubMed
  210. S. Perea, J. L. López-Ribot, B. L. Wickes et al., “Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis,” Antimicrobial Agents and Chemotherapy, vol. 46, no. 6, pp. 1695–1703, 2002. View at Publisher · View at Google Scholar
  211. P. Marichal, H. Vanden Bossche, F. C. Odds et al., “Molecular biological characterization of an azole-resistant Candida glabrata isolate,” Antimicrobial Agents and Chemotherapy, vol. 41, no. 10, pp. 2229–2237, 1997. View at Google Scholar
  212. Y. C. Chang, C. M. Bien, H. Lee, P. J. Espenshade, and K. J. Kwon-Chung, “Sre1p, a regulator of oxygen sensing and sterol homeostasis, is required for virulence in Cryptococcus neoformans,” Molecular Microbiology, vol. 64, no. 3, pp. 614–629, 2007. View at Publisher · View at Google Scholar · View at PubMed
  213. M. Nagi, H. Nakayama, K. Tanabe et al., “Transcription factors CgUPC2A and CgUPC2B regulate ergosterol biosynthetic genes in Candida glabrata,” Genes to Cells, vol. 16, no. 1, pp. 80–89, 2011. View at Publisher · View at Google Scholar · View at PubMed
  214. P. M. Silver, B. G. Oliver, and T. C. White, “Role of Candida albicans transcription factor Upc2p in drug resistance and sterol metabolism,” Eukaryotic Cell, vol. 3, no. 6, pp. 1391–1397, 2004. View at Publisher · View at Google Scholar · View at PubMed
  215. S. MacPherson, B. Akache, S. Weber, X. De Deken, M. Raymond, and B. Turcotte, “Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 5, pp. 1745–1752, 2005. View at Publisher · View at Google Scholar · View at PubMed
  216. B. Oliver, J. L. Song, J. H. Choiniere, and T. C. White, “cis-acting elements within the Candida albicans ERG11 promoter mediate the azole response through transcription factor Upc2p,” Eukaryotic Cell, vol. 6, no. 12, pp. 2231–2239, 2007. View at Publisher · View at Google Scholar · View at PubMed
  217. D. A. Stevens, T. C. White, D. S. Perlin, and C. P. Selitrennikoff, “Studies of the paradoxical effect of caspofungin at high drug concentrations,” Diagnostic Microbiology and Infectious Disease, vol. 51, no. 3, pp. 173–178, 2005. View at Publisher · View at Google Scholar · View at PubMed
  218. D. A. Stevens, M. Ichinomiya, Y. Koshi, and H. Horiuchi, “Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for β-1,6-glucan synthesis inhibition by caspofungin,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 9, pp. 3160–3161, 2006. View at Publisher · View at Google Scholar · View at PubMed
  219. J. M. Cota, J. L. Grabinski, R. L. Talbert et al., “Increases in SLT2 expression and chitin content are associated with incomplete killing of Candida glabrata by caspofungin,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 3, pp. 1144–1146, 2008. View at Publisher · View at Google Scholar · View at PubMed
  220. G. Chamilos, R. E. Lewis, N. Albert, and D. P. Kontoyiannis, “Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 6, pp. 2257–2259, 2007. View at Publisher · View at Google Scholar · View at PubMed
  221. F. S. Nolte, T. Parkinson, D. J. Falconer et al., “Isolation and characterization of fluconazole- and amphotericin B- resistant Candida albicans from blood of two patients with leukemia,” Antimicrobial Agents and Chemotherapy, vol. 41, no. 1, pp. 196–199, 1997. View at Google Scholar
  222. Y. Miyazaki, A. Geber, H. Miyazaki et al., “Cloning, sequencing, expression and allelic sequence diversity of ERG3 (C-5 sterol desaturase gene) in Candida albicans,” Gene, vol. 236, no. 1, pp. 43–51, 1999. View at Publisher · View at Google Scholar
  223. C. M. Martel, J. E. Parker, O. Bader et al., “Identification and characterization of four azole-resistant erg3 mutants of Candida albicans,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 11, pp. 4527–4533, 2010. View at Publisher · View at Google Scholar · View at PubMed
  224. H. Vanden Bossche, P. Marichal, and F. C. Odds, “Molecular mechanisms of drug resistance in fungi,” Trends in Microbiology, vol. 2, no. 10, pp. 393–400, 1994. View at Publisher · View at Google Scholar
  225. D. Sanglard, F. Ischer, T. Parkinson, D. Falconer, and J. Bille, “Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents,” Antimicrobial Agents and Chemotherapy, vol. 47, no. 8, pp. 2404–2412, 2003. View at Publisher · View at Google Scholar
  226. P. F. Watson, M. E. Rose, and S. L. Kelly, “Isolation and analysis of ketoconazole resistant mutants of Saccharomyces cerevisiae,” Journal of Medical and Veterinary Mycology, vol. 26, no. 3, pp. 153–162, 1988. View at Google Scholar
  227. L. Young, C. Hull, and J. Heitman, “Disruption of ergosterol biosynthesis confers resistance to amphotericin B in Candida lusitaniae,” Antimicrobial Agents and Chemotherapy, vol. 47, no. 9, pp. 2717–2724, 2003. View at Publisher · View at Google Scholar
  228. K. L. Jensen-Pergakes, M. A. Kennedy, N. D. Lees, R. Barbuch, C. Koegel, and M. Bard, “Sequencing, disruption, and characterization of the Candida albicans sterol methyltransferase (ERG6) gene: drug susceptibility studies in erg6 mutants,” Antimicrobial Agents and Chemotherapy, vol. 42, no. 5, pp. 1160–1167, 1998. View at Google Scholar
  229. S. Kelly, D. C. Lamb, D. E. Kelly et al., “Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol Δ5,6-desaturation,” FEBS Letters, vol. 400, no. 1, pp. 80–82, 1997. View at Publisher · View at Google Scholar
  230. P. Vandeputte, G. Tronchin, T. Bergès, C. Hennequin, D. Chabasse, and J. -P. Bouchara, “Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 3, pp. 982–990, 2007. View at Publisher · View at Google Scholar · View at PubMed
  231. P. Vandeputte, G. Tronchin, G. Larcher et al., “A nonsense mutation in the ERG6 gene leads to reduced susceptibility to polyenes in a clinical isolate of Candida glabrata,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 10, pp. 3701–3709, 2008. View at Publisher · View at Google Scholar · View at PubMed
  232. P. K. Mukherjee and J. Chandra, “Candida biofilm resistance,” Drug Resistance Updates, vol. 7, no. 4-5, pp. 301–309, 2004. View at Publisher · View at Google Scholar · View at PubMed
  233. L. R. Martinez, M. R. Mihu, G. Han et al., “The use of chitosan to damage Cryptococcus neoformans biofilms,” Biomaterials, vol. 31, no. 4, pp. 669–679, 2010. View at Publisher · View at Google Scholar · View at PubMed
  234. R. K. Pettit, K. K. Repp, and K. C. Hazen, “Temperature affects the susceptibility of Cryptococcus neoformans biofilms to antifungal agents,” Medical Mycology, vol. 48, no. 2, pp. 421–426, 2010. View at Publisher · View at Google Scholar
  235. P. Hamal, J. Ostransky, M. Dendis et al., “A case of endocarditis caused by the yeast Pichia fabianii with biofilm production and developed in vitro resistance to azoles in the course of antifungal treatment,” Medical Mycology, vol. 46, no. 6, pp. 601–605, 2008. View at Publisher · View at Google Scholar · View at PubMed
  236. G. Di Bonaventura, A. Pompilio, C. Picciani, M. Iezzi, D. D'Antonio, and R. Piccolomini, “Biofilm formation by the emerging fungal pathogen Trichosporon asahii: development, architecture, and antifungal resistance,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 10, pp. 3269–3276, 2006. View at Publisher · View at Google Scholar · View at PubMed
  237. A. Ueno, T. Hamano, A. Fujii et al., “The effects of voriconazole and vascular lesions in invasion of aspergillosis into the central nerve system,” Clinical Neurology, vol. 49, no. 8, pp. 468–473, 2009. View at Google Scholar
  238. M. J. Seidler, S. Salvenmoser, and F. M. C. Müller, “Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 11, pp. 4130–4136, 2008. View at Publisher · View at Google Scholar · View at PubMed
  239. P. H. Chandrasekar and E. K. Manavathu, “Do Aspergillus species produce biofilm?” Future Microbiology, vol. 3, no. 1, pp. 19–21, 2008. View at Publisher · View at Google Scholar · View at PubMed
  240. M. M. Harriott and M. C. Noverr, “Candida albicans and Staphylococcus aureus form polymicrobial biofilms: effects on antimicrobial resistance,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 9, pp. 3914–3922, 2009. View at Publisher · View at Google Scholar · View at PubMed
  241. G. E. Pierce, “Pseudomonas aeruginosa, Candida albicans, and device-related nosocomial infections: implications, trends, and potential approaches for control,” Journal of Industrial Microbiology and Biotechnology, vol. 32, no. 7, pp. 309–318, 2005. View at Publisher · View at Google Scholar · View at PubMed
  242. J. Chandra, G. Zhou, and M. A. Ghannoum, “Fungal biofilms and antimycotics,” Current Drug Targets, vol. 6, no. 8, pp. 887–894, 2005. View at Publisher · View at Google Scholar
  243. M. Jabra-Rizk, W. A. Falkler, and T. F. Meiller, “Fungal biofilms and drug resistance,” Emerging Infectious Diseases, vol. 10, no. 1, pp. 14–19, 2004. View at Google Scholar
  244. R. Di Santo, “Natural products as antifungal agents against clinically relevant pathogens,” Natural Product Reports, vol. 27, no. 7, pp. 1084–1098, 2010. View at Publisher · View at Google Scholar · View at PubMed
  245. T. Arif, J. D. Bhosale, N. Kumar et al., “Natural products - Antifungal agents derived from plants,” Journal of Asian Natural Products Research, vol. 11, no. 7, pp. 621–638, 2009. View at Publisher · View at Google Scholar · View at PubMed
  246. A. M. Mayer, A. D. Rodríguez, R. G. S. Berlinck, and N. Fusetani, “Marine pharmacology in 2007-8: marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the immune and nervous system, and other miscellaneous mechanisms of action,” Comparative Biochemistry and Physiology, vol. 153, no. 2, pp. 191–222, 2011. View at Publisher · View at Google Scholar · View at PubMed
  247. O. Marchetti, J. M. Entenza, D. Sanglard, J. Bille, M. P. Glauser, and P. Moreillon, “Fluconazole plus cyclosporine: a fungicidal combination effective against experimental due to Candida albicans,” Antimicrobial Agents and Chemotherapy, vol. 44, no. 11, pp. 2932–2938, 2000. View at Publisher · View at Google Scholar
  248. O. Marchetti, P. Moreillon, M. P. Glauser, J. Bille, and D. Sanglard, “Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans,” Antimicrobial Agents and Chemotherapy, vol. 44, no. 9, pp. 2373–2381, 2000. View at Publisher · View at Google Scholar
  249. M. C. Cruz, L. M. Cavallo, J. M. Görlach et al., “Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and TOR kinase homologs in Cryptococcus neoformans,” Molecular and Cellular Biology, vol. 19, no. 6, pp. 4101–4112, 1999. View at Google Scholar
  250. M. C. Cruz, M. Del Poeta, P. Wang et al., “Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin,” Antimicrobial Agents and Chemotherapy, vol. 44, no. 1, pp. 143–149, 2000. View at Google Scholar
  251. M. C. Cruz, A. L. Goldstein, J. Blankenship et al., “Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 11, pp. 3162–3170, 2001. View at Publisher · View at Google Scholar · View at PubMed
  252. R. D. Cannon, E. Lamping, A. R. Holmes et al., “Efflux-mediated antifungal drug resistance,” Clinical Microbiology Reviews, vol. 22, no. 2, pp. 291–321, 2009. View at Publisher · View at Google Scholar · View at PubMed
  253. M. Dryden and P. Payne, “Preventing parasites in cats,” Veterinary Therapeutics, vol. 6, no. 3, pp. 260–267, 2005. View at Google Scholar
  254. M. Sharma, R. Manoharlal, S. Shukla et al., “Curcumin modulates efflux mediated by yeast ABC multidrug transporters and is synergistic with antifungals,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 8, pp. 3256–3265, 2009. View at Publisher · View at Google Scholar · View at PubMed
  255. J. Pachl, P. Svododa, F. Jacobs et al., “A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis,” Clinical Infectious Diseases, vol. 42, no. 10, pp. 1404–1413, 2006. View at Publisher · View at Google Scholar · View at PubMed
  256. T. Bader, K. Schröppel, S. Bentink, N. Agabian, G. Köhler, and J. Morschhäuser, “Role of calcineurin in stress resistance, morphogenesis, and virulence of a Candida albicans wild-type strain,” Infection and Immunity, vol. 74, no. 7, pp. 4366–4369, 2006. View at Publisher · View at Google Scholar · View at PubMed
  257. J. Blankenship, F. L. Wormley, M. K. Boyce et al., “Calcineurin is essential for Candida albicans survival in serum and virulence,” Eukaryotic Cell, vol. 2, no. 3, pp. 422–430, 2003. View at Publisher · View at Google Scholar
  258. A. Odom, S. Muir, E. Lim, D. L. Toffaletti, J. Perfect, and J. Heitman, “Calcineurin is required for virulence of Cryptococcos neoformans,” The EMBO Journal, vol. 16, no. 10, pp. 2576–2589, 1997. View at Publisher · View at Google Scholar · View at PubMed
  259. D. Sanglard, F. Ischer, O. Marchetti, J. Entenza, and J. Bille, “Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence,” Molecular Microbiology, vol. 48, no. 4, pp. 959–976, 2003. View at Publisher · View at Google Scholar
  260. W. J. Steinbach, R. A. Cramer, B. Z. Perfect et al., “Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus,” Eukaryotic Cell, vol. 5, no. 7, pp. 1091–1103, 2006. View at Publisher · View at Google Scholar · View at PubMed
  261. P. C. Ting, R. Kuang, H. Wu et al., “The synthesis and structure-activity relationship of pyridazinones as glucan synthase inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 21, no. 6, pp. 1819–1822, 2011. View at Publisher · View at Google Scholar · View at PubMed
  262. G. Zhou, P. C. Ting, R. Aslanian et al., “SAR studies of pyridazinone derivatives as novel glucan synthase inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 21, no. 10, pp. 2890–2893, 2011. View at Publisher · View at Google Scholar · View at PubMed
  263. S. S. Walker, Y. Xu, I. Triantafyllou et al., “Discovery of a novel class of orally active antifungal {beta}-1,3-D-glucan synthase inhibitors,” Antimicrob Agents Chemother, vol. 55, no. 11, pp. 5099–5106, 2011. View at Google Scholar
  264. J. Oh, E. Fung, U. Schlecht et al., “Gene annotation and drug target discovery in Candida albicans with a tagged transposon mutant collection,” PLoS Pathogens, vol. 6, no. 10, Article ID e1001140, 2010. View at Publisher · View at Google Scholar · View at PubMed
  265. D. Xu, B. Jiang, T. Ketela et al., “Genome-wide fitness test and mechanism-of-action studies of inhibitory compounds in Candida albicans,” PLoS pathogens, vol. 3, no. 6, p. e92, 2007. View at Publisher · View at Google Scholar · View at PubMed
  266. R. Pukkila-Worley, E. Holson, F. Wagner, and E. Mylonakis, “Antifungal drug discovery through the study of invertebrate model hosts,” Current Medicinal Chemistry, vol. 16, no. 13, pp. 1588–1595, 2009. View at Publisher · View at Google Scholar
  267. T. Roemer, B. Jiang, J. Davison et al., “Large-scale essential gene identification in Candida albicans and applications to antifungal drug discovery,” Molecular Microbiology, vol. 50, no. 1, pp. 167–181, 2003. View at Publisher · View at Google Scholar
  268. W. Hu, S. Sillaots, S. Lemieux et al., “Essential gene identification and drug target prioritization in Aspergillus fumigatus,” PLoS Pathogens, vol. 3, no. 3, p. e24, 2007. View at Publisher · View at Google Scholar · View at PubMed
  269. V. Bruno and A. Mitchell, “Large-scale gene function analysis in Candida albicans,” Trends in Microbiology, vol. 12, no. 4, pp. 157–161, 2004. View at Publisher · View at Google Scholar · View at PubMed
  270. C. Nobile and A. Mitchell, “Large-scale gene disruption using the UAU1 cassette,” Methods in Molecular Biology, vol. 499, pp. 175–194, 2009. View at Publisher · View at Google Scholar
  271. C. Nobile and A. Mitchell, “Regulation of cell-surface genes and biofilm formation by the C. albicans transcription factor Bcr1p,” Current Biology, vol. 15, no. 12, pp. 1150–1155, 2005. View at Publisher · View at Google Scholar · View at PubMed
  272. V. M. Bruno, S. Kalachikov, R. Subaran, C. J. Nobile, C. Kyratsous, and A. P. Mitchell, “Control of the C. albicans cell wall damage response by transcriptional regulator Cas5,” PLoS Pathogens, vol. 2, no. 3, Article ID e21, pp. 0204–0210, 2006. View at Publisher · View at Google Scholar · View at PubMed
  273. E. Epp, G. Vanier, D. Harcus et al., “Reverse genetics in Candida albicans predicts ARF cycling is essential for drug resistance and virulence,” PLoS Pathogens, vol. 6, no. 2, Article ID e1000753, 2010. View at Publisher · View at Google Scholar · View at PubMed
  274. O. R. Homann, J. Dea, S. M. Noble, and A. D. Johnson, “A phenotypic profile of the Candida albicans regulatory network,” PLoS Genetics, vol. 5, no. 12, Article ID e1000783, 2009. View at Publisher · View at Google Scholar · View at PubMed
  275. S. Noble and A. Johnson, “Strains and strategies for large-scale gene deletion studies of the diploid human fungal pathogen Candida albicans,” Eukaryotic Cell, vol. 4, no. 2, pp. 298–309, 2005. View at Publisher · View at Google Scholar · View at PubMed
  276. E. Epp, A. Walther, G. Lépine et al., “Forward genetics in Candida albicans that reveals the Arp2/3 complex is required for hyphal formation, but not endocytosis,” Molecular Microbiology, vol. 75, no. 5, pp. 1182–1198, 2010. View at Publisher · View at Google Scholar · View at PubMed
  277. O. W. Liu, C. D. Chun, E. D. Chow, C. Chen, H. D. Madhani, and S. M. Noble, “Systematic genetic analysis of virulence in the human fungal pathogen Cryptococcus neoformans,” Cell, vol. 135, no. 1, pp. 174–188, 2008. View at Publisher · View at Google Scholar · View at PubMed
  278. G. Chamilos, C. J. Nobile, V. M. Bruno, R. E. Lewis, A. P. Mitchell, and D. P. Kontoyiannis, “Candida albicans Cas5, a regulator of cell wall integrity, is required for virulence in murine and toll mutant fly models,” The Journal of Infectious Diseases, vol. 200, no. 1, pp. 152–157, 2009. View at Publisher · View at Google Scholar · View at PubMed
  279. R. Pukkila-Worley, A. Y. Peleg, E. Tampakakis, and E. Mylonakis, “Candida albicans hyphal formation and virulence assessed using a caenorhabditis elegans infection model,” Eukaryotic Cell, vol. 8, no. 11, pp. 1750–1758, 2009. View at Publisher · View at Google Scholar · View at PubMed
  280. P. Vandeputte, F. Ischer, D. Sanglard, and A. T. Coste, “In vivo systematic analysis of Candida albicans Zn2-Cys6 transcription factors mutants for mice organ colonization,” Plos One, vol. 6, no. 10, p. e26962, 2011. View at Google Scholar
  281. S. M. Noble, S. French, L. A. Kohn, V. Chen, and A. D. Johnson, “Systematic screens of a Candida albicans homozygous deletion library decouple morphogenetic switching and pathogenicity,” Nature Genetics, vol. 42, no. 7, pp. 590–598, 2010. View at Publisher · View at Google Scholar · View at PubMed